Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma
- 1 October 1987
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 28 (2) , 151-155
- https://doi.org/10.1016/0090-8258(87)90208-3
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignanciesGynecologic Oncology, 1986
- Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group studyGynecologic Oncology, 1985
- Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatinCancer, 1984
- Estrogen and progesterone receptors in ovarian neoplasmsGynecologic Oncology, 1983
- TAMOXIFEN THERAPY FOR ADVANCED OVARIAN-CANCER1982
- ESTROGEN-RECEPTORS IN OVARIAN EPITHELIAL CARCINOMA1982
- Advanced ovarian carcinoma: Response to antiestrogen therapyCancer, 1981
- High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapyGynecologic Oncology, 1981
- MEDROXYPROGESTERONE ACETATE FOR TREATMENT OF METASTATIC AND RECURRENT OVARIAN CARCINOMA1977
- PROGESTOGEN THERAPY FOR OVARIAN CARCINOMABJOG: An International Journal of Obstetrics and Gynaecology, 1972